NeuroSense (NRSN) director details options and restricted share holdings

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. director Mark Leuchtenberger filed an initial ownership report showing his existing equity position in the company. The filing lists options to purchase 192,000 ordinary shares at an exercise price of $3.51 per share, expiring on October 31, 2031, which are fully vested and exercisable.

He also reports direct holdings of ordinary shares in several blocks, including 128,000 shares, 75,000 shares, and 122,951 restricted shares. Some of these restricted shares are scheduled to vest on December 30, 2026 and January 30, 2027, subject to his continued service and the achievement of specified business milestones.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Leuchtenberger Mark

Role Director

Type	Security	Shares	Price	Value
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Options to Purchase Ordinary Shares — 192,000 shares (Direct); Ordinary Shares — 325,951 shares (Direct)

Footnotes (3)

1. F1. These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
2. F2. These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
3. F3. These options are fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 03/18/2026 - 03:35 PM Learn about SEC filing dates

FAQ

What does NeuroSense (NRSN) director Mark Leuchtenberger report in this Form 3?

He reports his existing equity holdings in NeuroSense, including ordinary shares and stock options. The filing shows multiple share blocks and one option grant, establishing his initial reported ownership position as a director of the company.

How many NeuroSense (NRSN) shares are covered by Mark Leuchtenberger’s options?

He reports options to purchase 192,000 ordinary shares of NeuroSense. These options carry an exercise price of $3.51 per share and an expiration date of October 31, 2031, and are described as fully vested and exercisable in the footnotes.

What ordinary share holdings does Mark Leuchtenberger disclose in NeuroSense (NRSN)?

He discloses several direct ordinary share positions, including 128,000 shares, 75,000 shares, and 122,951 restricted shares. These entries reflect different blocks of NeuroSense ordinary shares held directly, with some subject to vesting conditions described in the footnotes.

When do Mark Leuchtenberger’s restricted NeuroSense (NRSN) shares vest?

Certain restricted shares are scheduled to vest on December 30, 2026 and January 30, 2027. Vesting requires his continued service to NeuroSense and may accelerate if specified business milestones in the restricted share agreements are achieved.

Are Mark Leuchtenberger’s NeuroSense (NRSN) options already exercisable?

Yes. A footnote states that the reported options to purchase ordinary shares are fully vested and exercisable. The options cover 192,000 underlying ordinary shares at an exercise price of $3.51 per share and expire on October 31, 2031.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Leuchtenberger Mark

(Last) (First) (Middle)

C/O NEUROSENSE THERAPEUTICS LTD.

11 HAMENOFIM STREET, BUILDING B

(Street)

HERZLIYA 4672562

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NeuroSense Therapeutics Ltd. [ NRSN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	128,000	D
Ordinary Shares(1)	75,000(1)	D
Ordinary Shares(2)	122,951(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(3)	01/01/2022	10/31/2031	Ordinary Shares	192,000(3)	$3.51	D

Explanation of Responses:

1. These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.

2. These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.

3. These options are fully vested and exercisable.

	/s/ Mark Leuchtenberger	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)